Collaborative Practice Agreements

The following pharmacists have provided the Board with a collaborative practice agreement for prescribing, modifying, continuing, or discontinuing a Schedule II-V drug and may be eligible to obtain a mid-level practitioner registration from DEA for the prescribing only of such drug. Such activities must be performed in compliance with § 54.1-3300.1, 18VAC110-40-10 et seq., and federal laws.

NOTE: Unless approval is required as outlined in 18VAC110-40-30, collaborative practice agreements involving Schedule VI drugs only do not need to be submitted to the Board prior to implementation.